Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | CDC25B | P30305 | 1/20 | 0.34 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.33 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.32 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.32 |
| ▸ | KDR | P35968 | 1/20 | 0.32 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.31 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.30 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1344662 | 0.83 | SMN1; SMN2 (0.48) | LMNASMN1; SMN2CDC25BHCAR2NAPRT | |
| Hydrochloric Acid SCHEMBL4826150 | 0.81 | SMN1; SMN2 (0.47) | LMNASMN1; SMN2CDC25BHCAR2NAPRT | |
| SCHEMBL6856427 | 0.81 | SIRT3 (0.41) | LMNASMN1; SMN2SIRT6 | |
| SCHEMBL3705950 | 0.81 | SMN1; SMN2 (0.34) | LMNASMN1; SMN2CDC25BHCAR2KDR | |
| SCHEMBL27725504 | 0.77 | ABL1 (0.38) | SMN1; SMN2HCAR2GPBAR1 | |
| SCHEMBL23001626 | 0.76 | CDC25B (0.34) | LMNASMN1; SMN2CDC25BGPBAR1CSNK2A1 | |
| SCHEMBL8828506 | 0.76 | PIK3C3 (0.41) | SMN1; SMN2GPBAR1ALDH1A1ALOX15 | |
| SCHEMBL30843825 | 0.76 | GSK3B (0.37) | LMNASMN1; SMN2CDC25BKDR | |
| SCHEMBL27809895 | 0.76 | LMNA (0.35) | LMNASMN1; SMN2CDC25BHCAR2GPBAR1 | |
| SCHEMBL20303956 | 0.76 | CSNK2A1 (0.45) | LMNASMN1; SMN2CSNK2A1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114989123-B | Flavone-3-carboxylic acid compound, bactericidal composition containing same and application thereof | 长江大学 | 2024-05-31 | — | — | CN | disclosed |
| CN-114989123-A | Flavone-3-carboxylic acid compound, bactericidal composition containing compound and application | 长江大学 | 2022-09-02 | — | — | CN | disclosed |
| US-20080293696-A1 | 2-Aminoarylcarboxamides Useful as Cancer Chemotherapeutic Agents | BAYER PHARMACEUTICALS CORPORATION (US) | 2008-11-27 | — | — | US | disclosed |
| US-7323474-B2 | Pyridine derivatives inhibiting angiogenesis and/or VEGF receptor tyrosine kinase | NOVARTIS AG (CH) | 2008-01-29 | — | — | US | disclosed |
| EP-1765811-A2 | 2-AMINOARYLCARBOXAMIDES USEFUL AS CANCER CHEMOTHERAPEUTIC AGENTS | Bayer Pharmaceuticals Corporation (US) | 2007-03-28 | — | — | EP | disclosed |
| WO-2006002383-A2 | 2-AMINOARYLCARBOXAMIDES USEFUL AS CANCER CHEMOTHERAPEUTIC AGENTS | BAYER PHARMACEUTICALS CORPORATION (US) | 2006-01-05 | — | — | WO | disclosed |
| EP-1254138-B1 | PYRIDINE DERIVATIVES INHIBITING ANGIOGENESIS AND/OR VEGF RECEPTOR TYROSINE KINASE | NOVARTIS AG (CH) | 2005-05-11 | — | — | EP | disclosed |
| US-20040209894-A1 | Pyridine derivatives inhibiting angiogenesis and/or VEGF receptor tyrosine kinase | BOLD GUIDO | 2004-10-21 | — | — | US | disclosed |
| US-6706731-B2 | WITH ISOQUINOLINE DERIVATIVES AS ANTITUMOR AGENTS | NOVARTIS AG (CH) | 2004-03-16 | — | — | US | disclosed |
| US-20030158409-A1 | Pyridine derivatives inhibiting angiogenesis and/or vegf receptor tyrosine kinase | NOVARTIS AG (CH) | 2003-08-21 | — | — | US | disclosed |
| EP-1254138-A1 | PYRIDINE DERIVATIVES INHIBITING ANGIOGENESIS AND/OR VEGF RECEPTOR TYROSINE KINASE | Novartis AG (CH) | 2002-11-06 | — | — | EP | disclosed |
| WO-2001058899-A1 | PYRIDINE DERIVATIVES INHIBITING ANGIOGENESIS AND/OR VEGF RECEPTOR TYROSINE KINASE | NOVARTIS AG (CH) | 2001-08-16 | — | — | WO | disclosed |
| US-4556709-A | BACTERICIDES, FEED ADDITIVES | BAYER AKTIENGESELLSCHAFT (DE) | 1985-12-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040209894-A1 | Pyridine derivatives inhibiting angiogenesis and/or VEGF receptor tyrosine kinase | FLT1, FLT4, KDR | LMNA 4241/4885SMN1; SMN2 4360/4885CDC25B 726/4885 |
| US-20080293696-A1 | 2-Aminoarylcarboxamides Useful as Cancer Chemotherapeutic Agents | ABCC3, HCCS, ABCC2 | LMNA 2261/4885SMN1; SMN2 2708/4885CDC25B 734/4885 |
| US-20030158409-A1 | Pyridine derivatives inhibiting angiogenesis and/or vegf receptor tyrosine kinase | FLT1, FLT4, KDR | LMNA 4369/4885SMN1; SMN2 4475/4885CDC25B 672/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.